Comparison of the safety and efficacy of biodegradable polymer biolimus-eluting stents and durable polymer everolimus-eluting stents: Propensity score-matched analysis

Objectives We investigated and compared the clinical outcomes between biodegradable polymer biolimus-eluting stents (BES) and durable polymer everolimus-eluting stents (EES) in a single-center prospective registry. Background There is limited data regarding the safety and efficacy of the biodegradable BES compared to second-generation drug-eluting stents. Methods From January 2010 to April 2012, a total of 1,279 patients were treated with BES (n=647) or EES (n=632) in a single center. We included 1,231 patients (BES=625, EES=606) after excluding 48 patients (BES=22, EES=26) with acute myocardial infarction accompanied by cardiogenic shock. The 1-year incidences of target lesion failure (TLF), patient-oriented composite outcomes (POCO), and stent thrombosis (ST) after the index procedure were compared in propensity score-matched analyses. Results Propensity score matching yielded 406 well-balanced pairs (EES=406, BES-B=406). In the propensity-matched population, the 1-year incidence of TLF (BES=3.0% vs. EES=2.5%, P=0.666) and POCO (BES=5.4% vs. EES=6.4%, P=0.552) were similar between the 2 groups. In addition, the incidence of definite or probable ST was also similar (BES=0.74% vs. EES=0.74%, P=1.000). In subgroup analysis, the number of patients who reached the primary end-point did not differ significantly between the 2 groups. Conclusion In a single-center registry with unrestricted use of EES and BES-B, these stents showed comparable efficacy and safety in terms of TLF, POCO, and ST at 1-year follow-up. (J Interven Cardiol 2014;27:399-407)